The production of a European vaccine against the coronavirus will begin in September, said the head of the Italian biotech company Irbm Piero Di Lorenzo.
Work on the drug called ChAdOx1 are British and Italian specialists, in particular, the multinational pharmaceutical group AstraZeneca scientists at Oxford University and specialists of the Irbm working in the field of molecular biotechnology.
Nearly 140 thousand people are willing to volunteer in testing a vaccine against coronavirus in the United States, said the newspaper USA Today, citing the chief of the country infectious diseases Anthony Fauci.
According to her, the trials enrolled 138 600 people, almost equal to the number of deaths of patients with the coronavirus in the United States.
The head of the Russian direct investment Fund Kirill Dmitriev has denied the charges of London in an attempt to steal information about the development of a vaccine against coronavirus.
Earlier in the British cyber security centre said that over the years, hackers have carried out attacks on various organizations that participated in the creation of the drug from COVID-19. In London believe that the perpetrators "almost certainly" relate to the Russian intelligence service.
Vaccine Anglo-Swedish company AstraZeneca and Moderna American are one of the leading candidates among the 15 vaccines from COVID-19, which pass clinical trials in humans, said at a briefing in Geneva principal investigator who Sumia Swaminathan.
"The good news is that we have about 200 vaccines, which are at different stages of the tests. Of these, about 15 are already testing vaccines on people," she said.
The health Ministers of Italy, Germany, France and the Netherlands signed a contract with Anglo-Swedish pharmaceutical company Astrazeneca for the production of 400 million doses of vaccines against coronavirus, said the head of the Italian offices Roberto Speranza.
According to him, the vaccine will be "intended for the population of Europe."
The final stage of clinical trials of three vaccines against coronavirus in the United States may begin in the summer, reports the Wall Street Journal.
According to the Director of the Center for vaccine research at the National Institute of Allergy and infectious diseases John Maskaly, the third - final - stage trials will be held in dozens of US cities.
British pharmaceutical company AstraZeneca has more than doubled production capacity for production of vaccines against coronavirus - up to 2 billion doses, the company said on Thursday.
The increase will become possible as a result of two agreements: the coalition for innovation in the field of preparedness for epidemics (CEPI) and the Global Alliance for vaccines and immunization (GAVI), as well as with the state vaccine Institute of India (Serum Institute of India).